Search research articles
Contact Us
Filters
Showing results (11-20 of 54) with videos related to
Page
of 6
Sort By:
Current Medical Research and Opinion
|
October 27, 2007
Subcutaneous injection pain with C.E.R.A., a continuous erythropoietin receptor activator, compared with darbepoetin alfa
Anne Pannier, Paul Jordan, Frank C Dougherty, et al.
Journal of Cardiovascular Pharmacology
|
November 25, 2011
No evidence of QT prolongation with supratherapeutic doses of aleglitazar
Stefan Sturm, Darren Bentley, Paul Jordan, et al.
Plos Pathogens
|
December 16, 2021
Comparison of RNA synthesis initiation properties of non-segmented negative strand RNA virus polymerases
Afzaal M Shareef, Barbara Ludeke, Paul Jordan, et al.
Expert Opinion on Investigational Drugs
|
December 1, 2010
Aleglitazar, a balanced PPARα/γ agonist, has no clinically relevant pharmacokinetic interaction with high-dose atorvastatin or rosuvastatin
Adam J Foley-Comer, Anne-Marie Young, Fiona Russell-Yarde, et al.
Clinical Chemistry
|
February 22, 2013
A comparison of the theoretical relationship between HDL size and the ratio of HDL cholesterol to apolipoprotein A-I with experimental results from the Women's Health Study
Norman A Mazer, Franco Giulianini, Nina P Paynter, et al.
Journal of Investigative Medicine : the Official Publication of the American Federation for Clinical Research
|
October 2, 2009
Laboratory markers as predictors of mortality in patients with Clostridium difficile infection
Chaitanya Pant, Phillip Madonia, Anil Minocha, et al.
Scientometrics
|
March 19, 2016
Automated Research Impact Assessment: A New Bibliometrics Approach
Christina H Drew, Kristianna G Pettibone, Fallis Owen Finch, et al.
Pathophysiology : the Official Journal of the International Society for Pathophysiology
|
August 19, 2017
Two year follow-up of Crohn's patients substituted to certolizumab anti-TNFa therapy: SAVANT 2
Andrew Motlis, Moheb Boktor, Paul Jordan, et al.
Current Medical Research and Opinion
|
June 3, 2008
The effect of severe hepatic impairment on the pharmacokinetics and haematological response of C.E.R.A
Viera Kupcová, Jan Sperl, Anne Pannier, et al.
Journal of Clinical Pharmacology
|
October 27, 2007
Pharmacokinetic and pharmacodynamic properties of methoxy polyethylene glycol-epoetin beta are unaffected by the site of subcutaneous administration
Steven Fishbane, Anne Pannier, Xavier Liogier, et al.
Page
of 6
Search research articles
Search
Showing results (11-20 of 54) with videos related to
Sort By:
Page
of 6
Current Medical Research and Opinion
|
October 27, 2007
Subcutaneous injection pain with C.E.R.A., a continuous erythropoietin receptor activator, compared with darbepoetin alfa
Anne Pannier, Paul Jordan, Frank C Dougherty, et al.
Journal of Cardiovascular Pharmacology
|
November 25, 2011
No evidence of QT prolongation with supratherapeutic doses of aleglitazar
Stefan Sturm, Darren Bentley, Paul Jordan, et al.
Plos Pathogens
|
December 16, 2021
Comparison of RNA synthesis initiation properties of non-segmented negative strand RNA virus polymerases
Afzaal M Shareef, Barbara Ludeke, Paul Jordan, et al.
Expert Opinion on Investigational Drugs
|
December 1, 2010
Aleglitazar, a balanced PPARα/γ agonist, has no clinically relevant pharmacokinetic interaction with high-dose atorvastatin or rosuvastatin
Adam J Foley-Comer, Anne-Marie Young, Fiona Russell-Yarde, et al.
Clinical Chemistry
|
February 22, 2013
A comparison of the theoretical relationship between HDL size and the ratio of HDL cholesterol to apolipoprotein A-I with experimental results from the Women's Health Study
Norman A Mazer, Franco Giulianini, Nina P Paynter, et al.
Journal of Investigative Medicine : the Official Publication of the American Federation for Clinical Research
|
October 2, 2009
Laboratory markers as predictors of mortality in patients with Clostridium difficile infection
Chaitanya Pant, Phillip Madonia, Anil Minocha, et al.
Scientometrics
|
March 19, 2016
Automated Research Impact Assessment: A New Bibliometrics Approach
Christina H Drew, Kristianna G Pettibone, Fallis Owen Finch, et al.
Pathophysiology : the Official Journal of the International Society for Pathophysiology
|
August 19, 2017
Two year follow-up of Crohn's patients substituted to certolizumab anti-TNFa therapy: SAVANT 2
Andrew Motlis, Moheb Boktor, Paul Jordan, et al.
Current Medical Research and Opinion
|
June 3, 2008
The effect of severe hepatic impairment on the pharmacokinetics and haematological response of C.E.R.A
Viera Kupcová, Jan Sperl, Anne Pannier, et al.
Journal of Clinical Pharmacology
|
October 27, 2007
Pharmacokinetic and pharmacodynamic properties of methoxy polyethylene glycol-epoetin beta are unaffected by the site of subcutaneous administration
Steven Fishbane, Anne Pannier, Xavier Liogier, et al.
Page
of 6